title: Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
abstract: Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.
authors.affiliation: University of Alabama at Birmingham, Birmingham, AL 35233-0007, USA. grizzle@path.uab.edu
authors.forename: William E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: Bao-Ling L
authors.initials: BL
authors.lastname: Adam
authors.forename: William L
authors.initials: WL
authors.lastname: Bigbee
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Conrads
authors.forename: Christopher
authors.initials: C
authors.lastname: Carroll
authors.forename: Ziding
authors.initials: Z
authors.lastname: Feng
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Izbicka
authors.forename: Moncef
authors.initials: M
authors.lastname: Jendoubi
authors.forename: Donald
authors.initials: D
authors.lastname: Johnsey
authors.forename: Jacob
authors.initials: J
authors.lastname: Kagan
authors.forename: Robin J
authors.initials: RJ
authors.lastname: Leach
authors.forename: Diane B
authors.initials: DB
authors.lastname: McCarthy
authors.forename: O John
authors.initials: OJ
authors.lastname: Semmes
authors.forename: Shiv
authors.initials: S
authors.lastname: Srivastava
authors.forename: Sudhir
authors.initials: S
authors.lastname: Srivastava
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
authors.forename: Mark D
authors.initials: MD
authors.lastname: Thornquist
authors.forename: Mukesh
authors.initials: M
authors.lastname: Verma
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Zou
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis*; D000465:Algorithms; D001798:Blood Proteins / Q000032:analysis*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D012107:Research Design; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D001798:Blood Proteins